Shares of TG Therapeutics Inc (NASDAQ:TGTX) have received a consensus rating of “Buy” from the seven ratings firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $14.95.
Several analysts recently commented on the company. BidaskClub raised TG Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. B. Riley assumed coverage on TG Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $10.00 price objective on the stock. Zacks Investment Research upgraded TG Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a research report on Friday, November 16th. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of TG Therapeutics in a research report on Monday, November 12th. Finally, ValuEngine upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, October 24th.
NASDAQ:TGTX traded down $0.01 during trading hours on Friday, reaching $4.91. 106,515 shares of the company traded hands, compared to its average volume of 1,282,654. The stock has a market capitalization of $407.86 million, a price-to-earnings ratio of -2.57 and a beta of 1.84. TG Therapeutics has a 1 year low of $3.32 and a 1 year high of $17.35.
TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Friday, November 9th. The biopharmaceutical company reported ($0.43) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.12. TG Therapeutics had a negative return on equity of 185.20% and a negative net margin of 99,001.33%. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. Sell-side analysts predict that TG Therapeutics will post -2.03 EPS for the current fiscal year.
In other news, CFO Sean A. Power sold 37,275 shares of the business’s stock in a transaction dated Wednesday, January 2nd. The stock was sold at an average price of $4.13, for a total value of $153,945.75. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 15.10% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the stock. Rhumbline Advisers lifted its holdings in TG Therapeutics by 18.3% during the second quarter. Rhumbline Advisers now owns 54,587 shares of the biopharmaceutical company’s stock worth $718,000 after buying an additional 8,435 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of TG Therapeutics by 11.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 276,325 shares of the biopharmaceutical company’s stock valued at $3,633,000 after purchasing an additional 29,012 shares during the last quarter. Highland Capital Management LP lifted its holdings in shares of TG Therapeutics by 60.5% during the 3rd quarter. Highland Capital Management LP now owns 753,151 shares of the biopharmaceutical company’s stock valued at $4,218,000 after purchasing an additional 283,910 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of TG Therapeutics by 19.3% during the 2nd quarter. Northern Trust Corp now owns 751,725 shares of the biopharmaceutical company’s stock valued at $9,885,000 after purchasing an additional 121,424 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of TG Therapeutics by 221.5% during the 2nd quarter. Bank of America Corp DE now owns 101,704 shares of the biopharmaceutical company’s stock valued at $1,337,000 after purchasing an additional 70,070 shares during the last quarter. Institutional investors own 57.30% of the company’s stock.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
Read More: The mechanics of the bid-ask spread in trading
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.